Company Filing History:
Years Active: 1995-1999
Title: Michael R De Felippis: Innovator in Insulin Analog Formulations
Introduction
Michael R De Felippis is a prominent inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of insulin analogs. With a total of 5 patents to his name, De Felippis continues to push the boundaries of medical innovation.
Latest Patents
Among his latest patents, De Felippis has developed formulations for monomeric insulin analogs. One of his notable inventions discloses various parenteral pharmaceutical formulations that provide a protracted effect. These formulations comprise a sterile aqueous suspension of insulin analog, sodium chloride, a physiologically acceptable buffer, zinc ions, and a preservative, all maintained at a specific pH. Another patent focuses on monomeric insulin analog formulations that include zinc, protamine, and phenolic derivatives, which are designed to offer a prolonged duration of action.
Career Highlights
De Felippis is currently associated with Eli Lilly and Company, a leading pharmaceutical firm known for its innovative healthcare solutions. His work at Eli Lilly has allowed him to contribute to advancements in diabetes treatment through his patented formulations.
Collaborations
Throughout his career, De Felippis has collaborated with notable colleagues, including Bruce H Frank and James H Anderson, Jr. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking pharmaceutical solutions.
Conclusion
Michael R De Felippis stands out as a key figure in the field of insulin analog formulations. His innovative patents and contributions to Eli Lilly and Company highlight his commitment to improving healthcare through scientific advancements.